13 results about "Diclofenac" patented technology

The invention provides an application of Exifenone in preparation of a medicine for treating diabetic retinopathy, the Exifenone can be combined near a K412 lactic acid modification site of HDAC1, so that the lactic acid modification of the K412 site of the HDAC1 is specifically inhibited, the deacetylation activity of the HDAC1 to H3K56 is enhanced, the transcriptional activation of VEGFA (vascular endothelial growth factor A) mediated by H3K56ac and pathological angiogenesis are inhibited, and the effect of treating diabetic retinopathy is achieved. Further, vascular pathological injury caused by diabetic retinopathy is improved. The application provides a new target and a candidate drug for clinical treatment of diabetic retinopathy. The research result of the application provides experimental evidence for the epoxybenzophenone to be used for clinical specific treatment of diabetic retinopathy.

Hydroalcoholic single phase gel compositions comprising diclofenac or a pharmaceutically acceptable salt of diclofenac are disclosed. The compositions are single phase compositions, and don't contain a lipophilic phase. The compositions can comprise at least one non-ionic surfactant. The compositions are useful in the topical delivery of diclofenac. The compositions can be used in the treatment of for example pain.

The invention relates to aqueous, oral formulations of diclofenac that provide both rapid and sustained relief from acute pain. The invention further relates to pharmaceutical compositions comprising the compounds, methods of making the aqueous pharmaceutical compositions and methods of using the compounds treating pain, including, but not limited to migraines.

The utility model discloses a device for measuring the migration amount of dichlorphenol in a food contact material, and relates to the technical field of food safety detection, in particular to a device for measuring the migration amount of dichlorphenol in a food contact material, which comprises a measuring disc assembly, the measuring disc assembly comprises a measuring disc body, and an inner flange is arranged on the inner side of the upper part of the measuring disc body; an outer clamping edge is arranged on the outer side of the upper portion of the measuring disc body, positioning tool inserting holes are formed in the periphery of the bottom of the measuring disc body, spring positioning columns are fixedly connected to the lower portion of the measuring disc body, and a positioning tool assembly is inserted into the upper portions of the positioning tool inserting holes. According to the device for measuring the migration amount of the diclofen in the food contact material, through the cooperative arrangement of the measuring disc assembly, the measuring cover assembly, heat insulation cotton and reflective paper, the device for measuring the migration amount of the diclofen in the food contact material has the effect of simulating measurement of various environments; therefore, the device for measuring the migration amount of the diclofen in the food contact material has the effect of improving the measuring efficiency.

The present application relates to the technical field of medicine, and especially relates to a combined Chinese and western medicine composition and application thereof, wherein the combined Chinese and western medicine composition comprises Chinese patent medicine and western medicine; the raw material of the Chinese patent medicine comprises Strychnos seed powder, Earthworm, Codonopsis, Poria cocos, Atractylodes, Chuanxiong, Salvia miltiorrhiza, Panax notoginseng, Radix et Rhizoma Bovis, and Radix Glycyrrhizae; and the effective component of the western medicine is diclofenac; the application of the combined Chinese and western medicine composition in preparation of a lumbar pain medicine; the application is for preparation of intervertebral disc-derived lumbar pain medicines of different syndromes; the syndrome is preferably qi and blood deficiency syndrome; the combined Chinese and western medicine composition can effectively treat intervertebral disc-derived lumbar pain of different syndromes through mutual cooperation between the Chinese patent medicine and the western medicine, and the curative effect is more obvious for intervertebral disc-derived lumbar pain of qi and blood deficiency syndrome.

The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions of pancreatitis, hepatitis, arthritis and the like, ameliorate organ injury and inflammatory indexes, and have better effects than positive control drug, indometacin. Compared with the conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.

This invention provides the application of exifone in the preparation of drugs for treating diabetic retinopathy. Exifone binds near the lactation modification site of HDAC1 K412, thereby specifically inhibiting the lactation modification of HDAC1 at the K412 site. This leads to enhanced deacetylation activity of HDAC1 on H3K56, thereby inhibiting H3K56ac-mediated VEGFA transcriptional activation and pathological angiogenesis, and thus improving the vascular pathological damage of diabetic retinopathy. This application provides a new target and candidate drug for the clinical treatment of diabetic retinopathy. The research results of this application provide experimental evidence that exifone can be used as a clinically specific treatment for diabetic retinopathy.

The present application relates to a kind of diclofenac-methotrexate co-amorphous substance and its preparation method and application, in the diclofenac-methotrexate co-amorphous substance, the molar ratio of diclofenac and methotrexate is 1:2, its X-ray powder diffraction pattern has no sharp diffraction peak, indicating the formation of co-amorphous form.The present application is obtained by using rotary evaporation method to obtain co-amorphous substance, and the results of pharmacokinetics and in vitro and in vivo pharmacodynamics experiments show that the performance indicators such as DIC-MTX co-amorphous system are superior to physical mixture in bioavailability, anti-inflammatory effect, etc., which embodies its potential application value, and shows that there is positive effect between the two drugs for treating rheumatoid arthritis, which provides a research basis for realizing the combination of DIC and MTX.

The invention discloses a cinacalcet salt of diclofenac as well as a pharmaceutical composition and medical application of the cinacalcet salt, provides the cinacalcet salt of the diclofenac as shown in a formula (I), and further provides a pharmaceutical composition containing the cinacalcet salt of the diclofenac and a PD-1 / PD-L1 inhibitor. The diclofenac cinacalcet salt and the pharmaceutical composition of the diclofenac cinacalcet salt can be used for preparing drugs for preventing and / or treating cancers, infectious diseases, fibrosis diseases, autoimmune diseases and painful diseases.

The invention relates to a diclofenac-methotrexate co-amorphous substance and a preparation method and application thereof, in the diclofenac-methotrexate co-amorphous substance, the molar ratio of diclofenac to methotrexate is 1: 2, and the X-ray powder diffraction pattern of the diclofenac-methotrexate co-amorphous substance has no sharp diffraction peak, indicating the formation of the co-amorphous state. The co-amorphous substance is obtained through a rotary evaporation method, pharmacokinetic and in-vivo and in-vitro pharmacodynamic experiment results show that the DIC-MTX co-amorphous system is superior to a physical mixture in bioavailability, anti-inflammatory effect and other performance indexes, the potential application value of the DIC-MTX co-amorphous system is embodied, and the DIC-MTX co-amorphous system has good application prospects. Moreover, the two medicines have a positive effect of treating rheumatoid arthritis, and a research basis is provided for realizing the drug combination of the DIC and the MTX.

The invention discloses marine streptomyces DCF24 and an application of the marine streptomyces DCF24 in degradation of chlorphenyl compounds. The marine streptomyces DCF24 is preserved in the China Center for Type Culture Collection on November 27, 2024, and the preservation number of the marine streptomyces DCF24 is CCTCC NO: M 20242649. The streptomyces marinus DCF24 is applied to degradation of chlorphenyl compounds, particularly has high capacity of degrading the non-steroidal anti-inflammatory drug diclofenac, can degrade for 7 days under the anaerobic condition, has the degradation rate of 95%, is suitable for treating pollution of the non-steroidal anti-inflammatory drug diclofenac in the environment, and can achieve the purpose of environmental remediation.

The present inventors primarily aimed to provide an ointment containing diclofenac sodium in which the formation of diclofenac analogs is suppressed. [Solution] The above problem can be solved by an ointment containing diclofenac sodium and oleic acid, wherein the oleic acid content is below a predetermined concentration.